Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mycoplasma bovis strain HB150 live vaccine
- Development stage
- Unknown
- Lead developer
- Spirit Jinyu Biological Pharmaceutical
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intranasal
01
Overview
The Mycoplasma bovis strain HB150 live vaccine is a veterinary biologic developed for the prevention of infections caused by *Mycoplasma bovis* in cattle, particularly bovine respiratory disease (BRD). The vaccine is based on a live attenuated strain, HB150, which was derived from a virulent field isolate (HB0801) through 150 serial passages in vitro. This attenuation process results in the loss of key virulence factors while maintaining immunogenicity. The vaccine stimulates both systemic and mucosal immune responses, including the production of specific antibodies and T-cell mediated immunity, providing protection against pneumonia and lung lesions associated with *M. bovis* infection. It was primarily developed by researchers at Huazhong Agricultural University and was approved as a new veterinary drug in China.
- Other names
- live vaccine for mycoplasma bovis (strain HB150)M. bovis HB150 live attenuated vaccineMycoplasma bovis Live Vaccine (Strain HB150)
02
Targets
M. bovis (Mycoplasma bovis)
Beyond the preview
Go deeper on mycoplasma bovis strain HB150 live vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mycoplasma bovis strain HB150 live vaccine.